Participants were randomly assigned to one of five therapies: exenatide alone, dapagliflozin alone, dual therapy of exenatide and dapagliflozin, combined dapagliflozin and metformin therapy, or the weight-loss medication phentermine/topiramate extended-release
They are not medications and do not replace prescribed GLP-1 receptor agonist treatments
Combining both with GLP-1 treatment produces significantly better lean mass preservation outcomes than either intervention alone, and far better than the drug alone
Dose adjustment considerations If dry mouth is severe and persistent, your provider may consider slowing dose escalation, reducing the current dose, or switching to a different GLP-1 medication
The effects of Metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome
69 MenniC.HernandezM